INS and fatty liver disease: Oral administration of scopolin in an OVX-induced obesity mouse model revealed that scopolin prevented OVX-induced weight gain, an increase in body fat percentage, hepatic steatosis, and an increase in epididymal fat by downregulating serum leptin and insulin levels.